CMA costs case improves access to justice

The UK Supreme Court ruling involving Pfizer and Flynn is important for any company considering an appeal against the regulator, say Sophie Lawrance and James Batsford of Bristows.

• WTO's COVID deal: more vaccine ‘enabler’ than IP waiver?
• Gilenya injunction bid: big pharma takeaways
• Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox

More features